The Asia Pacific Telmisartan Market would witness market growth of 7.2% CAGR during the forecast period (2020-2026). Telmisartan is considered as a prescription medication, which is frequently suggested to ease down and broaden blood vessels in persons having elevated blood pressure.
Telmisartan means a set of drugs called as angiotensin II receptor blockers (ARBs). Telmisartan could be utilized alone or in combination with other medications like hydrochlorothiazide with an aim to treat elevated blood pressure.
The growth of the Telmisartan market would be supplemented by the increasing number of supportive government policies for hypertension management. For example, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) introduced, ‘India Hypertension Management Initiative (IHMI)’. The IHMI focuses to decrease death & disability associated with cardiovascular disease (CVD), by enhancing control over elevated blood pressure (hypertension), lowering down salt consumption from food, and cutting down artificial trans-fats, which are supporting the risks for creating CVD.
The Hypertension market dominated the Malaysia Telmisartan Market by Indication in 2019, thereby, achieving a market value of $45.1 million by 2026. The Cardiovascular Risk Reduction market is expected to witness a CAGR of 9% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: Telmisartan Market in Asia Pacific is expected to register a CAGR of 7.2% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
By Indication
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 